230 related articles for article (PubMed ID: 21423266)
1. Multiparametric MRI is helpful to predict tumor focality, stage, and size in patients diagnosed with unilateral low-risk prostate cancer.
Delongchamps NB; Beuvon F; Eiss D; Flam T; Muradyan N; Zerbib M; Peyromaure M; Cornud F
Prostate Cancer Prostatic Dis; 2011 Sep; 14(3):232-7. PubMed ID: 21423266
[TBL] [Abstract][Full Text] [Related]
2. Detection of prostate cancer with magnetic resonance imaging: optimization of T1-weighted, T2-weighted, dynamic-enhanced T1-weighted, diffusion-weighted imaging apparent diffusion coefficient mapping sequences and MR spectroscopy, correlated with biopsy and histopathological findings.
Aydin H; Kizilgöz V; Tatar IG; Damar C; Ugan AR; Paker I; Hekimoğlu B
J Comput Assist Tomogr; 2012; 36(1):30-45. PubMed ID: 22261768
[TBL] [Abstract][Full Text] [Related]
3. Peripheral zone prostate cancer localization by multiparametric magnetic resonance at 3 T: unbiased cancer identification by matching to histopathology.
Selnæs KM; Heerschap A; Jensen LR; Tessem MB; Schweder GJ; Goa PE; Viset T; Angelsen A; Gribbestad IS
Invest Radiol; 2012 Nov; 47(11):624-33. PubMed ID: 23011187
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.
Yoshizako T; Wada A; Hayashi T; Uchida K; Sumura M; Uchida N; Kitagaki H; Igawa M
Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184
[TBL] [Abstract][Full Text] [Related]
5. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy.
Haider MA; Chung P; Sweet J; Toi A; Jhaveri K; Ménard C; Warde P; Trachtenberg J; Lockwood G; Milosevic M
Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):425-30. PubMed ID: 17881141
[TBL] [Abstract][Full Text] [Related]
6. The predictive value of endorectal 3 Tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer.
Somford DM; Hamoen EH; Fütterer JJ; van Basten JP; Hulsbergen-van de Kaa CA; Vreuls W; van Oort IM; Vergunst H; Kiemeney LA; Barentsz JO; Witjes JA
J Urol; 2013 Nov; 190(5):1728-34. PubMed ID: 23680307
[TBL] [Abstract][Full Text] [Related]
7. [Quantitative dynamic MRI and localisation of non-palpable prostate cancer].
Cornud F; Beuvon F; Thévenin F; Chauveinc L; Vieillefond A; Descazeaux A; Flam T
Prog Urol; 2009 Jun; 19(6):401-13. PubMed ID: 19467459
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging.
Tanimoto A; Nakashima J; Kohno H; Shinmoto H; Kuribayashi S
J Magn Reson Imaging; 2007 Jan; 25(1):146-52. PubMed ID: 17139633
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-to-total prostate-specific antigen ratio in the detection of prostate cancer.
Vilanova JC; Barceló-Vidal C; Comet J; Boada M; Barceló J; Ferrer J; Albanell J
AJR Am J Roentgenol; 2011 Jun; 196(6):W715-22. PubMed ID: 21606259
[TBL] [Abstract][Full Text] [Related]
10. Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4-10 ng/mL: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging.
Tamada T; Sone T; Higashi H; Jo Y; Yamamoto A; Kanki A; Ito K
AJR Am J Roentgenol; 2011 Sep; 197(3):664-70. PubMed ID: 21862809
[TBL] [Abstract][Full Text] [Related]
11. Locally recurrent prostate cancer after high-dose-rate brachytherapy: the value of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging in localizing tumors.
Tamada T; Sone T; Jo Y; Hiratsuka J; Higaki A; Higashi H; Ito K
AJR Am J Roentgenol; 2011 Aug; 197(2):408-14. PubMed ID: 21785087
[TBL] [Abstract][Full Text] [Related]
12. Endorectal 3D T2-weighted 1mm-slice thickness MRI for prostate cancer staging at 1.5Tesla: should we reconsider the indirects signs of extracapsular extension according to the D'Amico tumor risk criteria?
Cornud F; Rouanne M; Beuvon F; Eiss D; Flam T; Liberatore M; Zerbib M; Delongchamps NB
Eur J Radiol; 2012 Apr; 81(4):e591-7. PubMed ID: 21871750
[TBL] [Abstract][Full Text] [Related]
13. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer.
Hara N; Okuizumi M; Koike H; Kawaguchi M; Bilim V
Prostate; 2005 Feb; 62(2):140-7. PubMed ID: 15389803
[TBL] [Abstract][Full Text] [Related]
14. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer.
Horiguchi A; Nakashima J; Horiguchi Y; Nakagawa K; Oya M; Ohigashi T; Marumo K; Murai M
Prostate; 2003 Jun; 56(1):23-9. PubMed ID: 12746843
[TBL] [Abstract][Full Text] [Related]
15. MRI techniques for prediction of local tumor progression after high-intensity focused ultrasonic ablation of prostate cancer.
Kim CK; Park BK; Lee HM; Kim SS; Kim E
AJR Am J Roentgenol; 2008 May; 190(5):1180-6. PubMed ID: 18430829
[TBL] [Abstract][Full Text] [Related]
16. Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2-weighted, dynamic contrast-enhanced and diffusion-weighted imaging.
Delongchamps NB; Rouanne M; Flam T; Beuvon F; Liberatore M; Zerbib M; Cornud F
BJU Int; 2011 May; 107(9):1411-8. PubMed ID: 21044250
[TBL] [Abstract][Full Text] [Related]
17. Multiparametric magnetic resonance imaging for the assessment of extracapsular invasion and other staging parameters in patients with prostate cancer candidates for radical prostatectomy.
Lista F; Gimbernat H; Cáceres F; Rodríguez-Barbero JM; Castillo E; Angulo JC
Actas Urol Esp; 2014 Jun; 38(5):290-7. PubMed ID: 24387827
[TBL] [Abstract][Full Text] [Related]
18. Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor--correlation with biopsy findings.
Rouvière O; Valette O; Grivolat S; Colin-Pangaud C; Bouvier R; Chapelon JY; Gelet A; Lyonnet D
Urology; 2004 May; 63(5):922-7. PubMed ID: 15134982
[TBL] [Abstract][Full Text] [Related]
19. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer.
Haider MA; van der Kwast TH; Tanguay J; Evans AJ; Hashmi AT; Lockwood G; Trachtenberg J
AJR Am J Roentgenol; 2007 Aug; 189(2):323-8. PubMed ID: 17646457
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the potential of diffusion-weighted imaging in prostate cancer detection.
Morgan VA; Kyriazi S; Ashley SE; DeSouza NM
Acta Radiol; 2007 Jul; 48(6):695-703. PubMed ID: 17611881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
